BTK and BCL-2 Inhibitors in the First-Line Treatment of Chronic Lymphocytic Leukemia in High-Risk Patients: Systematic Review and Network Meta-Analysis
DOI:
https://doi.org/10.32635/2176-9745.RBC.2024v70n2.4501Keywords:
Leukemia, Lymphocytic, Chronic, B-Cell, Tyrosine Protein Kinase Inhibitors, Antineoplastic Protocols/venetoclax, Systematic Review, Network Meta-AnalysisAbstract
Introduction: Patients with high-risk chronic lymphocytic leukemia (CLL) have lower response rates, a more aggressive clinical course, and resistance to standard chemotherapy, representing a treatment challenge. Bruton's tyrosine kinase inhibitors (BTK – ibrutinib and acalabrutinib) and the BCL-2 inhibitor (venetoclax) can be used in these cases. Objective: To identify and evaluate studies on the efficacy and safety of the use of ibrutinib, acalabrutinib and venetoclax in first-line treatment in patients with high-risk CLL. Method: Systematic review of randomized clinical trials that evaluated adult patients with CLL, carriers of 17p deletion or TP53 mutation and without prior treatment. The PubMed, EMBASE, LILACS and Cochrane Library databases were searched, and the risk of bias was assessed using the Cochrane RoB 2 tool and the quality of evidence was assessed with GRADE. Results: In the network meta-analysis for progression-free survival (PFS) venetoclax + obinutuzumab (RR: 0.62; 95%CI 0.41-0.95; p value 0.027) and acalabrutinib + obinutuzumab (RR: 0. 74; 95% CI 0.55-0.99; p value 0.043) presented a lower risk of progression or death, with significance considered borderline. Ibrutinib + obinutuzumab (RR: 0.93; 95% CI 0.86-1.00; p value 0.054) did not show a significant difference in PFS for patients with high-risk CLL. Conclusion: First-line treatment with BTK inhibitors (ibrutinib and acalabrutinib) and the BCL-2 inhibitor (venetoclax) associated with anti-CD20 monoclonal agents – especially obinutuzumab – have been proposed as the standard for most patients with CLL. However, based on the results of this review with network meta-analysis, it was not possible to confirm this recommendation.
Downloads
References
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90. DOI: https://doi.org/10.1182/blood-2016-01-643569
Scarfò L, Ferreri AJM, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169-82. doi: http://dx.doi.org/10.1016/j.critrevonc.2016.06.003 DOI: https://doi.org/10.1016/j.critrevonc.2016.06.003
Rodrigues CA, Gonçalves MV, Ikoma MRV, et al. Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. Rev Bras Hematol Hemoter. 2016;38(4):346-57. DOI: https://doi.org/10.1016/j.bjhh.2016.07.004
National Cancer Institute [Internet]. Washington, DC: NCI; 2023. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Leukemia — Chronic Lymphocytic Leukemia (CLL) [acesso 2023 ago 31]. Disponível em: https://seer.cancer.gov/statfacts/html/clyl.html
Instituto Nacional de Câncer. Estimativa 2023: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA 2022. [acesso 2023 ago 31]. Disponível em: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2023.pdf
Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23-33. doi: https://doi.org/10.1016/j.annonc.2020.09.019 DOI: https://doi.org/10.1016/j.annonc.2020.09.019
Campo E, Cymbalista F, Ghia P, et al. TP53 aberrations in chronic lymphocytic leukemia: An overview of the clinical implications of improved diagnostics. Haematologica. 2018;103(12):1956–68. DOI: https://doi.org/10.3324/haematol.2018.187583
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(71):1-9. doi: https://doi.org/10.1136/bmj.n71 DOI: https://doi.org/10.1136/bmj.n71
University of York. Centre for Reviews and Dissemination. York: University of York; 2019. PROSPERO - International prospective register of systematic reviews. 2023. [acesso 2023 ago 31]. Disponível em: https://www.crd.york.ac.uk/PROSPERO/
McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40-6. doi: https://doi.org/10.1016/j.jclinepi.2016.01.021 DOI: https://doi.org/10.1016/j.jclinepi.2016.01.021
Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):1-10. doi: https://doi.org/10.1186/s13643-016-0384-4 DOI: https://doi.org/10.1186/s13643-016-0384-4
RoB 2: Risk of Bias 2 [Internet]. Versão 2. [Copenhagen]: Cochrane Denmark; 2011. [acesso 2023 mar 9]. Disponível em: https://www.riskofbias.info/
GRADEpro GDT: GRADEpro Guideline Development Tool [Internet]. Hamilton: McMaster University and Evidence Prime; 2022. [acesso em 2023 ago 23]. Disponível em: https://www.gradepro.org/
ter Veer E, van Oijen MGH, van Laarhoven HWM. The use of (Network) meta-analysis in clinical oncology. Front Oncol. 2019;9:822. doi: https://doi.org/10.3389/fonc.2019.00822 DOI: https://doi.org/10.3389/fonc.2019.00822
Sadeghirad B, Foroutan F, Zoratti MJ, et al. Theory and practice of Bayesian and frequentist frameworks for network meta-analysis. BMJ Evidence-Based Med. 2023;28(3):204-9. DOI: https://doi.org/10.1136/bmjebm-2022-111928
Shiny: Pacote shiny aplicação web em R [Internet]. Versão NMA bin. [sem local]: Núcleo de Bioestatística e Bioinformática; 2024. [acesso em 2023 ago 23]. Disponível em: http://nbbinc.info/
Mbuagbaw L, Rochwerg B, Jaeschke R, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017;6(1):1-5. DOI: https://doi.org/10.1186/s13643-017-0473-z
Chaimani A, Caldwell DM, Li T, et el. Chapter 11: Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane handbook for systematic reviews of interventions: version 6.4 2023. London: Cochrane; 2023. [acesso em 2023 ago 23]. Disponível em: https://training.cochrane.org/handbook/current/chapter-11
Al-Sawaf O, Zhang C, Jin HY, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023;14(1):1-12. DOI: https://doi.org/10.1038/s41467-023-37648-w
Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment- naïve chronic lymphocytic leukemia. Leukemia. 2022;36(4):1171-5. DOI: https://doi.org/10.1038/s41375-021-01485-x
Moreno C, Greil R, Demirkan F, et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022;107(9):2108-20. DOI: https://doi.org/10.3324/haematol.2021.279012
Molica S, Giannarelli D, Montserrat E. Comparison between Venetoclax-based and Bruton tyrosine kinase inhibitor-based therapy as upfront treatment of chronic lymphocytic leukemia (CLL): a systematic review and network meta-analysis. Clin Lymphoma, Myeloma Leuk. 2021;21(4):216-23. doi: https://doi.org/10.1016/j.clml.2020.10.012 DOI: https://doi.org/10.1016/j.clml.2020.10.012
Sheng Z, Song S, Yu M, et al. Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis. Leuk Lymphomaernet]. 2020;61(14):3432-9. doi: https://doi.org/10.1080/10428194.2020.1811271 DOI: https://doi.org/10.1080/10428194.2020.1811271
Brugnolli A, Cavada L, Saiani L. II sistema GRADE. Assist Inferm Ricerca. 2014;33(4):924-6.
Downloads
Published
How to Cite
Issue
Section
License
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
This work is licensed under a Creative Commons Attribution 4.0 International License.
